Quantifying the titer and quality of adenovirus stocks.
The broad application of recombinant adenoviruses to the development of vaccines and gene therapy vectors has encouraged the development of molecular assays for the facile quantitation of adenoviral particles and the assignment of their infectious potency. The Genome Quantitation Assay (GQA) and the QPCR-Based Potency Assay (QPA) developed for adenoviruses offer the attributes of precision, rapidity, and high throughput either performed manually or facilitated by simple automated liquid handling systems. These assay attributes allow for accelerated process development support and product characterization and release. The assays for adenovirus could offer the additional advantage in that their quantitation is based on viral replication independent of cytopathology permitting quantitation of serotypes that cause minimal cytopathic effect (CPE) in 293 cells and specificity that allows the components of multivalent vaccines to be discriminated and quantitated for release.
Wang
Fubao
F
Vaccine and Biologics Research, Merck Research Laboratories, Merck & Co Inc, West Point, PA, USA.
Mathis
Bill C
BC
Montalvo
Allison
A
Wolf
Jayanthi J
JJ
Lewis
John A
JA
D000256:Adenoviridae / Q000235:genetics*; D002460:Cell Line / Q000821:virology; D004279:DNA, Viral / Q000032:analysis / Q000235:genetics; D005822:Genetic Vectors / Q000302:isolation & purification*; D006801:Humans; D007668:Kidney / Q000378:metabolism; D016133:Polymerase Chain Reaction / Q000379:methods*; D014779:Virus Replication
D004279:DNA, Viral